BR100 Increased By (0.39%)
BR30 Increased By (0.47%)
KSE100 Increased By (0.6%)
KSE30 Increased By (0.7%)
AGHA 6.55 Increased By ▲ 0.23 (3.64%)
BECO 4.40 Increased By ▲ 0.13 (3.04%)
BML 62.43 Decreased By ▼ -0.02 (-0.03%)
BOP 31.38 Increased By ▲ 0.15 (0.48%)
CNERGY 11.79 Increased By ▲ 0.20 (1.73%)
CSIL 5.95 Increased By ▲ 0.23 (4.02%)
FCCL 61.12 Decreased By ▼ -0.42 (-0.68%)
FFL 14.88 Decreased By ▼ -0.14 (-0.93%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.29 Increased By ▲ 0.03 (0.48%)
KOSM 6.00 Increased By ▲ 0.44 (7.91%)
LOTCHEM 24.85 Increased By ▲ 0.17 (0.69%)
MLCF 104.13 Increased By ▲ 0.05 (0.05%)
NBP 174.66 Decreased By ▼ -0.62 (-0.35%)
NCPL 52.83 Increased By ▲ 0.06 (0.11%)
NPL 54.48 Increased By ▲ 0.36 (0.67%)
OGDC 315.35 Increased By ▲ 1.96 (0.63%)
PACE 9.41 Increased By ▲ 0.21 (2.28%)
PAEL 35.62 Decreased By ▼ -0.18 (-0.5%)
PIBTL 13.71 Increased By ▲ 0.24 (1.78%)
PPL 223.38 Increased By ▲ 1.57 (0.71%)
PRL 80.79 Increased By ▲ 1.71 (2.16%)
PTC 47.15 Increased By ▲ 0.30 (0.64%)
SSGC 24.15 Increased By ▲ 0.28 (1.17%)
TBL 9.25 Decreased By ▼ -0.06 (-0.64%)
TELE 7.53 Increased By ▲ 0.14 (1.89%)
TPL 24.89 Decreased By ▼ -0.22 (-0.88%)
TPLP 12.88 Increased By ▲ 0.37 (2.96%)
TREET 26.10 Decreased By ▼ -0.15 (-0.57%)
TRG 53.75 Increased By ▲ 0.31 (0.58%)
World

UK approves Pfizer-BioNTech COVID-19 vaccine, first in the world

  • The vaccine will be made available across the UK from next week.
Published Updated
By

Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use and said that it will be rolled out from early next week.

A vaccine is seen as the best chance for the world to get back to some semblance of normality amid a global pandemic which has killed nearly 1.5 million people and upended the global economy.

“The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use,” the government said.

“The vaccine will be made available across the UK from next week.”

Britain’s vaccine committee will decide which priority groups will get the jab first such as care home residents, health and care staff, the elderly and people who are clinically extremely vulnerable.

Both Pfizer-BioNTech and U.S. biotech firm Moderna have reported preliminary findings of more than 90% effectiveness - an unexpectedly high rate - in trials of their vaccines, which are both based on new messenger RNA (mRNA) technology.

Pfizer said Britain’s emergency use authorization marks a historic moment in the fight against COVID-19.

“This authorization is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the U.K.,” said CEO Albert Bourla.

“As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world.”

Health Secretary Matt Hancock said the programme would begin early next week. Hospitals, he said, were already ready to receive it.

“It is very good news,” Hancock said.

Comments

Comments are closed for this article.